Lindernia ciliata Exhibits Anti-Diabetic effects in Streptozotocin-Induced Diabetic Model by Upregulation of GLUT-2 and GLUT-4 Gene Expression

Purpose: To evaluate anti-diabetic effects of phytoconstituents isolated from L. ciliata by using STZ-induced invivo diabetic model. Methods: Type 2 diabetes was induced in rats via intraperitoneal streptozotocin and nicotinamide (65–110mg/kg). Group 1(normal control) received 0.2% CMC (5mL/kg), Group 2 (diabetic control), Group 3 (diabetic) received exenatide (4μg/kg), while Groups 4 and 5 (diabetic) were treated with LCF-1(10 and 20mg/kg) respectively for 14 days. Blood glucose, GLP-1, DPP-4 inhibition, beta-cell regeneration, and GLUT-2/GLUT-4 gene expression were assessed. Results: In Group 2, body weight significantly decreased compared to Group 1. On the 14th day, blood glucose levels significantly decreased in the exenatide and LCF-1 treated groups compared to Group 2(p<0.01), indicating their anti-diabetic properties. LCF-1 exhibited a notable increase in GLP-1 secretion (p<0.001) and plasma insulin levels (p<0.05) compared to Group 1 and Group 3, suggesting its antidiabetic effect, partly via GLP-1 secretion promotion. Additionally, LCF-1 treatment led to significant increases in GLP-1 secretion (p<0.001), DPP-4 inhibition (p<0.05), serum insulin levels (p<0.05), and beta-cell regeneration. The LCF-1 treatment notably upregulated glucose transport gene expression compared to both untreated and control groups, indicating a potential enhancement in glucose uptake mechanisms. Conclusion: Our study concludes that LCF 1 act as a potent antidiabetic agent by stimulating pancreatic insulin release, increasing GLP-1 levels, DPP-4 inhibition, promoting beta cell regeneration and glucose transport gene expression in STZ induced diabetic model.